Meiramgul Tokbulatova

Dr. Meiramgul Tokbulatova

Department of Internal Medicine, NJSC "Kazakh National Medical University named after. S.D. Asfendiyarov",, Almaty, Kazakhstan
orcid
Heart. Science. Future.

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2025 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Closed access
DADana Akhmentayeva
Dana Akhmentayeva
Zhanar ToktarovaZhanar Toktarova
Zhanar Toktarova
Aigyul IzhanovaAigyul Izhanova
Aigyul Izhanova
Meiramgul TokbulatovaMeiramgul Tokbulatova
Meiramgul Tokbulatova
AIAssel Issabekova
Assel Issabekova
GZG. Kh. Zhansarina
G. Kh. Zhansarina
Introduction . Hyperglycemia is one of the most common pregnancy complications worldwide. The largest proportion of patients are women with gestational diabetes mellitus, followed by pregnant women with previously diagnosed type 1 and type 2 diabetes. Managing such cases is a complex clinical task requiring close cooperation between specialists in various fields. Aim . To analyze the tactics of managing pregnant women with diabetes mellitus to assess predisposing risk factors. Materials and methods. The analysis of modern data was carried out with an emphasis on the role of diabetes mellitus in developing complications during pregnancy. The databases PubMed, Scopus, Web of Science, and eLibrary were used for the analysis. The search was carried out by keywords: gestational diabetes mellitus, pregnancy complications, metabolic disorders, maternal-fetal outcomes, prevention of diabetes in pregnancy. Results . The level of metabolic control at the stage of pregnancy planning has a significant impact on its course and outcome in women with type 1 and type 2 diabetes mellitus. Pre-pregnancy training and professional support of qualified specialists play a key role, often surpassing мнеthe use of modern technologies such as insulin pumps and continuous glucose monitoring systems. Conclusion . Despite the existing methods of prevention and treatment, there remains a need for further study of individualized approaches to the management of pregnant women with metabolic disorders.

31 October 2016 in Наука и здравоохранение
Verified
Journal Article
Open access
АААймагамбетова А.о.
Аймагамбетова А.о.
КЛКаражанова Л.к.
Каражанова Л.к.
КАКотляр А.
Котляр А.
Meiramgul TokbulatovaMeiramgul Tokbulatova
Meiramgul Tokbulatova
Целью нашего исследования явилось изучение прогностической роли β-АРМ у больных инфарктом миокарда с подъемом сегмента ST(ИМпST). Материалы и методы: В представленном исследовании проводится изучение β-адренорецепции мембран эритроцитов (β-АРМ) у 81 больных инфарктом миокарда с подъемом сегмента ST с различным течением заболевания. β-адренореактивность организма, определяли по величине β-АРМ, с использованием диагностического набора реактивов «АРМ-Агат» (ООО «Агат-Мед», Москва). Все больные были разделены на 2 группы. 1-ю группу составили 49 больных, которые не имели осложнений, как в госпитальном периоде, так и после неё. Во 2-ю группу вошли остальные 32 больных с разными осложнениями сердечно-сосудистой системы. Результаты: У больных с ИМпST средняя величина β-АРМ в 2-х группах составила 29,9 ± 1,24 усл.ед. Средняя величина β-АРМ в 1-ой группе достоверно составила 34,07 ± 1,6 усл.ед (р<0,05). Во 2 –ой группе среднее значение β-АРМ составила 23,5 ± 1,31 усл.ед (р<0,05), против 19,2 ± 2,3 усл.ед (р<0,05) в контрольной группе. Полученные данные позволили сделать выводы, что исходные величины β-АРМ при ИМпST могут иметь прогностическое значение, в течении года от начала заболевания. У пациентов с ИМпST при низкой β-АРМ высока вероятность развития осложнении. При высоких показателях β-АРМ напротив, являются благоприятным прогностическим признаком Выводы: Таким образом, мы предполагаем, что у больных инфарктом миокарда с подъемом сегмента ST при β-АРМ менее 20 усл. ед., является неблагоприятным прогностическим показателем в развитии сердечно-сосудистых осложнении. Objective: The aim of our study was to evaluate the prognostic role of β-APM in patients for myocardial infarction with segment elevation ST (STEMI). Materials and Methods: In the present research, carried out the study of β-adrenoreception erythrocyte membranes (β-APM) in 81 patients with myocardial infarction with ST-segment elevation with a different course of the disease. β-adrenoreactivity of organism was determined by the value of β-APM using the diagnostic reagent kit "ARM-agate" (LLC "Agat-Med", Moscow). All patients were divided into 2 groups. 1st group consisted of 49 patients who did not have complications, both in hospital period and post it. In the 2nd group consisted of the 32 patients with different complications of the cardiovascular system. Results: In patients with STEMI average value of β-APM in the 2 groups was 29,9 ±1,24 The average value of β-APM in the first group was significantly 34,07 ±1,6 (p<0.05). In the 2 nd group, the mean value of β-APM was 23,5 ±1,31 (p<0.05), against 19,2 ±2,3 (p<0.05) in the control group, respectively. The findings led to the conclusion that the initial value of β-APM with STEMI may have prognostic value, within a year of onset. In patients with STEMI at a low β-APM were highly probability to develop complications. With high rates of β-APM in contrast, it is a favorable prognostic sign. Conclusions: Thus, we suggest that in patients of myocardial infarction with ST-segment elevation at the β-APM is less than 20 is a poor prognostic indicator in the development of cardiovascular complications. Мақсаты: SТ сегментінің көтерілуімен болатын миокард инфаркты кезіндегі β-АРМ болжамдық рөлін зерттеу. Құралдар мен әдістер: ST сегментінің көтерілуімен жүретін миокард инфаркт бар әр түрлі ағымдағы 81 науқастардың эритроциттерінің мембрана β-адренорецепциясын (β-АРМ) зерттеу әдісі жүргізілді. «АРМ-АГАТ» (Мәскеу) диагностикалық реактивтер жинағын қолда на отырып, ағзадағы β-АРМ анықталады. Барлық науқастар 2 топқа бөлінді.Бірінші топты стационарда жатқан кезеңде және стационардан шыққаннан кейін асқынуы жоқ 49 науқас құрады, екінші топты жүрек қантамыр жүйесінің әр түрлі асқынқынулары бар 32 науқас құрады. Нәтижелері: ST сегментінің жоғарылауымен жүретін миокард инфаркты бар 2 топтағы науқастарда β-АРМ орташа жоғарлауы 29,9 ±1,24 ш.б. (шартты бірлікті) құрады. 1 топта β-АРМ орташа жоғарлауы 34,07 ±1,6 ш.б. құрады. 2 топта β-АРМ орташа деңгейі 23,5±1,31 ш.б....

31 October 2016 in Наука и здравоохранение
Verified
Journal Article
Open access
АААймагамбетова А.о.
Аймагамбетова А.о.
КЛКаражанова Л.к.
Каражанова Л.к.
КАКотляр А.
Котляр А.
Meiramgul TokbulatovaMeiramgul Tokbulatova
Meiramgul Tokbulatova
Цель: Данная статья рассматривает изучение частот аллельных вариантов и генотипов цитокинов (TNF-α, IL-10, IL-6) у больных острым инфарктом миокарда с подъемом сегмента ST (ИМпST) у лиц русской национальности. Материалы и методы:Полиморфизм генов цитокинов исследовали методом рестриктного анализа продуктов амплификации специфических участков генома у 41 (69,5%) мужчин и 18 (30,5%) женщин, русской национальности.Контролем служила группа из 75 практически здоровых лиц (доноры русской национальности). У всех исследовался однонуклеотидный SNP-полиморфизм промоторного региона генов TNF-α (G–308A), IL-10 (G-1082A), IL-6 (G-174C). Диагноз ИМпST устанавливали в соответствии с классификацией Европейского общества кардиологов (ESC). Все больные были разделены на 2 группы, где группу неосложненного течения ИМпST составили 34 (57,6%) больных, которые не имели осложнений, как в госпитальном периоде, так и после неё. Вторую группу составили 25 (42,4%) пациентов с осложненным течением ИМпST. Результаты: В работе показана, ассоциация гомозиготного генотипа минорного типа А/А в позиции G–308A промоторной области гена TNFα с осложненным течением ИМпST (OR=6,72, р<0,05). Выявлено, что гомозиготный генотип минорного типа С/С в позиции G-174C промоторной области гена IL-6 также ассоциировал с осложненным течением ИМпST (OR=3,25, р<0,05). Согласно нашим данным, не было выявлено существенных различий в частоте аллелей и генотипов полиморфизма G-1082A гена IL-10 в зависимости от течения ИМпST. Таким образом, полиморфизмы генов цитокинов можно было бы рассматривать как возможный генетический фактор риска развития осложненного течения ИМпST у больных русской национальности (Восточно-Казахстанской области Республики Казахстан), после дополнительных исследовании с существенным увеличением объема выборки Objective: This article considers the study of the frequency of allelic variants and genotypes of cytokines (TNF-α, IL-10, IL-6) in patients of acute myocardial infarction with segment elevation ST (STEMI) in subjects of Russian nationality. Materials and Methods: The polymorphism of cytokine genes was examined by restriction analysis of specific areas of the genome amplification products in 41 (69.5%) men and 18 (30.5%) women of Russian nationality. Control group was consisted of 75 healthy subjects (donors of Russian nationality). In all subjects were studied single nucleotide polymorphism SNP-gene promoter region TNF-α (G-308A), IL-10 (G-1082A), IL-6 (G-174C). STEMI diagnosis was for accordance with the classification of the European Society of Cardiology (ESC). All patients were divided into 2 groups, where the group of uncomplicated STEMI amounted to 34 (57.6%) patients who did not have complications, both in hospital period and posthospital period. The second group was consisted of 25 (42.4%) patients with complicated course of STEMI. Results: In this paper shows, the association of the homozygous genotype minor type A / A in the position of G-308A promoter region of the TNFα gene with complicated STEMI (OR = 6,72, p<0.05). It was revealed that the minor type homozygous genotype C / C position of G-174C promoter region of the gene IL-6 is also associated with complicated STEMI (OR = 3,25, p<0.05). According to our results, there were no significant differences in the frequency of alleles and genotypes of polymorphism G-1082A gene IL-10, depending on the course of STEMI. Thus, polymorphisms of cytokine genes could be considered as a possible genetic risk factor for morbidity in patients with STEMI of Russian nationality (East Kazakhstan region of the Republic of Kazakhstan), after further study, with a significant increase the size of sample. Мақсаты: Ұлты орыс науқастардаST сегментінің көтерілуімен жүретін жедел миокард инфаркты кезіндегі цитокиндердің (TNF-α, IL-10, IL-6) аллель турінің және генотиптерініңжиілігін қарайтын мақала болып табылады Құралдар мен әдістер: Орыс ұлтты41 (69.5 %) ер адамдармен 18 (30.5 %) әйелдерде цитокиндер полиморфизмын, генініңспецификалық бөліктерініңамплификация өнімдерін, рестриктивті анализ әдісімензерттедік. Бақылаутобын 75 дені сау адамдар (орыс ұлтты донорлар) құрады. Барлығында гендердің TNF-альфа(G-308A), IL-10(G-1082A),...

30 October 2025 in Наука и здравоохранение
Verified
Journal Article
Open access
AZA.S. Zhunuspekova
A.S. Zhunuspekova
MAM.N. Akkaliyev
M.N. Akkaliyev
BAB.A. Ashirov
B.A. Ashirov
JMJamilya Mansurova
Jamilya Mansurova
Meiramgul TokbulatovaMeiramgul Tokbulatova
Meiramgul Tokbulatova
DND.T. Nurgalieva
D.T. Nurgalieva
We describe a case of ST-elevation myocardial infarction in a 74-year-old patient with peripheral artery disease. Despite dual antiplatelet therapy with high-dose clopidogrel, stent thrombosis and recurrent infarction occurred, requiring escalation to ticagrelor. Additionally, a low level of Klotho protein was detected, associated with increased risk of complications. This case highlights the importance of platelet function testing and emerging biomarkers for individualized therapy. Описан случай инфаркта миокарда с подъёмом ST у 74-летнего пациента с поражением периферических артерий. На фоне резистентности к клопидогрелю развился тромбоз стента и повторный инфаркт, что потребовало эскалации терапии до тикагрелора. Дополнительно выявлен низкий уровень белка Klotho, ассоциированный с высоким риском осложнений. Случай подчёркивает значимость тестирования функции тромбоцитов и поиска новых биомаркеров для индивидуализации терапии. 74 жастағы перифериялық артерия ауруы бар науқаста ST сегментінің көтерілуімен миокард инфарктісі жағдайы сипатталған. Жоғары дозадағы клопидогрелмен қос антитромбоцитарлық терапияға қарамастан, стент тромбозы және қайталама инфаркт дамыды, бұл тикагрелорға эскалацияны қажет етті. Сонымен қатар, асқыну қаупінің жоғарылауымен байланысты төмен Klotho ақуызының деңгейі анықталды. Бұл жағдай тромбоциттердің функциясын тестілеудің және жаңа биомаркерлерді қолданудың терапияны жекелендіру үшін маңыздылығын көрсетеді.

Verified
Journal Article
Open access
PDF file
JMJamilya Mansurova
Jamilya Mansurova
AKAnar Kozhabayeva
Anar Kozhabayeva
MKMirgul Kapakova
Mirgul Kapakova
AZAisulu Zhunuspekova
Aisulu Zhunuspekova
AAAinur Abylkhairova
Ainur Abylkhairova
AKAssel Kassymova
Assel Kassymova
Background: Whether plasma α-Klotho carries prognostic value in patients with acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI) is still unclear. Objectives: We set out to examine the links between plasma α-Klotho levels, routine clinical and laboratory findings, the occurrence of acute kidney injury (AKI), and cardiovascular mortality after PCI. Methods: Eighty-six patients with ACS treated by PCI were enrolled in this prospective study. Plasma α-Klotho was measured within 48 h of the procedure. Relationships were assessed by correlation analysis and logistic regression; cardiovascular mortality was tracked for 12 months. Results: Acute kidney injury developed in 30 patients (34.9%), and nine cardiovascular deaths (10.5%) occurred during the year of follow-up. α-Klotho showed positive correlations with platelet count, triglycerides and total protein, and inverse correlations with FIB-4, aspartate aminotransferase, creatinine, GRACE score, contrast volume and international normalized ratio. No significant link was found between α-Klotho and AKI (p = 0.882). Erythrocyte sedimentation rate (OR = 1.090; p < 0.001) and contrast volume (OR = 1.014; p = 0.007) remained independently associated with AKI. In univariable analysis higher α-Klotho levels were linked to lower cardiovascular mortality (OR = 0.648; p = 0.009). Conclusions: Higher plasma α-Klotho concentrations were associated with reduced odds of cardiovascular death in the univariable model. No association with AKI was detected. The mortality results should be regarded as exploratory and do not demonstrate an independent prognostic role.